Menarini Group – Product Pipeline Review – Q4 2010

Date: November 1, 2010
Pages: 50
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: MADA0DA6A58EN
Leaflet:

Download PDF Leaflet

Menarini Group – Product Pipeline Review – Q4 2010
Menarini Group – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Menarini Group – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Menarini Group – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Menarini Group human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Menarini Group with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Menarini Group’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Menarini Group’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Menarini Group in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Menarini Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Menarini Group.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Menarini Group and identify potential opportunities in those areas.
Menarini Group Snapshot
Menarini Group Overview
Key Information
Key Facts
Menarini Group – Research and Development Overview
Key Therapeutic Areas
Menarini Group – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Menarini Group – Pipeline Products Glance
Menarini Group – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Menarini Group Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Menarini Group – Drug Profiles
Abagovomab
  Product Description
  Mechanism of Action
  R&D Progress
Amediplase
  Product Description
  Mechanism of Action
  R&D Progress
Brivudin
  Product Description
  Mechanism of Action
  R&D Progress
Ibodutant
  Product Description
  Mechanism of Action
  R&D Progress
MEN16132
  Product Description
  Mechanism of Action
  R&D Progress
Nepadutant
  Product Description
  Mechanism of Action
  R&D Progress
Sabarubicin
  Product Description
  Mechanism of Action
  R&D Progress
Sabarubicin + cisplatin
  Product Description
  Mechanism of Action
  R&D Progress
Delimotecan
  Product Description
  Mechanism of Action
  R&D Progress
Sabarubicin
  Product Description
  Mechanism of Action
  R&D Progress
Menarini Group – Pipeline Analysis
Menarini Group – Pipeline Products by Therapeutic Class
Menarini Group Pipeline Products By Target
Menarini Group – Pipeline Products by Route of Administration
Menarini Group – Pipeline Products by Molecule Type
Menarini Group – Company Statement
Menarini Group – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jun 01, 2002: Preparation For Phase III Clinicals: ProMetic And Menarini Biotech Achieve Milestone For Amediplase Manufacture
Jun 01, 1997: A Report From The European Organization For Research And Treatment Of Cancer, Early Clinical Studies Group
Financial Deals Landscape
Menarini Group, Deals Volume Summary, 2004 to YTD 2010
Menarini Group, Deals Summary By Region, 2004 to YTD 2010
Menarini Group, Deals Summary, 2004 to YTD 2010
Menarini Group Detailed Deal Summary
Asset Purchase
PLIVA Sells AWD Manufacturing Plant In Germany
Technogenetics Signs Distribution Agreement With A. Menarini Diagnostics
Nanogen Enters Into An Agreement With A. Menarini Diagnostics
Spectral Diagnostics Enters Into Distribution Agreement With Menarini
ALK-Abello Enters Into An Agreement With Menarini
Licensing Agreements
Menarini Enters Into Licensing Agreement With Ipsen
CV Therapeutics Enters Into An Licensing Agreement With Menarini Group
Recordati Enters Into Licensing Agreement With The Menarini Group
The Menarini Group Enters Into License Agreement With Faes Farma
Oscient Pharmaceuticals Enters Into License Agreement With Menarini Group For FACTIVE
The Menarini Group Terminates License Agreement With Solagran
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Menarini Group – Pipeline by Therapy Area and Indication, 2010
Menarini Group – Pipeline by Stage of Development, 2010
Menarini Group – Monotherapy Products in Pipeline, 2010
Menarini Group – Combination Treatment Modalities in Pipeline, 2010
Menarini Group – Phase III, 2010
Menarini Group - Phase II, 2010
Menarini Group - Phase I, 2010
Menarini Group - Pipeline By Therapeutic Class, 2010
Menarini Group - Pipeline By Target, 2010
Menarini Group – Pipeline By Route of Administration, 2010
Menarini Group – Pipeline By Molecule Type, 2010
Menarini Group, Other Locations
Menarini Group, Subsidiaries
Menarini Group, Deals Summary, 2004 to YTD 2010
Menarini Group, Deals Summary by Region, 2004 to YTD 2010
Menarini Group, Deals Summary, 2004 to YTD 2010 36

LIST OF FIGURES

Menarini Group – Pipeline by Therapy Area and Indication, 2010
Menarini Group – Pipeline by Stage of Development, 2010
Menarini Group – Monotherapy Products in Pipeline, 2010
Menarini Group – Combination Treatment Modalities in Pipeline, 2010
Menarini Group – Pipeline By Therapeutic Class, 2010
Menarini Group - Pipeline By Target, 2010
Menarini Group – Pipeline By Route of Administration, 2010
Menarini Group – Pipeline By Molecule Type, 2010 29

Ask Your Question

Menarini Group – Product Pipeline Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: